Presymptom Health is a pioneering medtech company that creates diagnostic tests to detect illnesses earlier to help save lives.
Established to exploit a ground-breaking innovation to detect infection and sepsis in patients up to three days before symptoms appear, Presymptom has recently secured nearly £2M of seed funding and support to enable it to conduct its multisite NHS PRECISION clinical trial, which began enrolling in May 2021. The company is developing a clinical diagnostic portfolio that will ultimately include tests for use at both point-of-care and within central laboratory settings.
Nadia is an accomplished senior executive in the Life Sciences sector with experience across several therapeutic and diagnostic areas spanning EMEA, Asia Pacific and North America.
Iain Miller recently spoke to UK Innovation & Science Seed Fund for their CEO Spotlight.
Presymptom Health is open to investment discussions to join us on our journey to create a truly revolutionary test for sepsis.Find out more
Presymptom Health has a development plan to extend its clinical diagnostic test portfolio to include tests for both point of care and within central laboratories.Find out more